← Scroll for more →
Alnylam Pharmaceuticals, Inc. (ALNY)
Pharmaceutical Preparations
Latest Price
$165.00
TTM P/E
--
Normalized P/E
373.21
TTM Div Yield
--
Fwd Div Yield
--
Book Value
26.93
P/B Ratio
6.13
Valuation metrics
adjust assumptions →EPS: $2.33
Book value / share: $5.96
Formula: √(22.5 × EPS × BVPS)
Graham Number
$17.68
90% downside
Base FCF: $254M (median of recent 5yr)
Growth: 5%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$45.20
74% downside
EPS: $2.33
Target P/E: 15×
Formula: EPS × P/E
P/E Fair Value
$34.95
80% downside
Institutional Ownership
100.0% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| FMR LLC | 15.02M | $4.52B | 11.23% | +444.8K | 2026-06-30 |
| Capital World Investors | 11.14M | $3.35B | 8.33% | +342.5K | 2026-06-30 |
| BlackRock, Inc. | 10.91M | $3.28B | 8.16% | +462.8K | 2026-06-30 |
| Capital Research Global Investors | 9.75M | $2.94B | 7.29% | +279.5K | 2026-06-30 |
| Vanguard Portfolio Management LLC | 6.54M | $1.97B | 4.89% | +47.1K | 2026-06-30 |
| Vanguard Capital Management LLC | 6.03M | $1.81B | 4.51% | +82.8K | 2026-06-30 |
| T. Rowe Price Investment Management, Inc. | 5.64M | $1.70B | 4.22% | +448.8K | 2026-06-30 |
| Invesco Ltd. | 3.75M | $1.13B | 2.81% | +2.46M | 2026-06-30 |
| State Street Corp | 3.56M | $1.07B | 2.66% | +233.0K | 2026-06-30 |
| JPMorgan Chase & Co | 2.68M | $785.0M | 2.00% | -2.04M | 2026-06-30 |